Clinical Experience in Managing AEs in GPRC5D Therapy

Phase 3 DREAMM-7 and DREAMM-8 trial results showed that combinations with belantamab mafodotin showed superior efficacy vs standard of care in the disease.

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

ODAC voted against the favorability of the agent in combination with dexamethasone and pomalidomide or bortezomib in multiple myeloma.

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Treatment with ISB 2001 demonstrated robust responses across difficult-to-treat multiple myeloma subgroups in the phase 1 TRIgnite-1 study.

Longer follow-up from the phase 3 MIDAS trial may be necessary to evaluate progression-free survival and overall survival.